Article Text

PDF
CASE REPORT
Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy
  1. Neal Andruska1,
  2. Lily Mahapatra1,
  3. Carleigh Hebbard1,
  4. Priyank Patel2,
  5. Vishesh Paul3
  1. 1Internal Medicine, College of Medicine, University of Illinois, Urbana, Illinois, USA
  2. 2Hematology & Oncology, Carle Foundation Hospital, Urbana, Illinois, USA
  3. 3Pulmonology & Critical Care, Carle Foundation Hospital, Urbana, Illinois, USA
  1. Correspondence to Dr Neal Andruska, nandrus2{at}illinois.edu, nandrus59{at}gmail.com

Summary

Anti-programmed death 1 (PD-1) immune checkpoint inhibitors enhance the antitumour activity of the immune system and have produced durable tumour responses in several solid tumours including non-small cell lung cancer (NSCLC). However, PD-1 inhibitors can lead to immune-related adverse events , including pneumonitis, which is typically mild, but can be severe and potentially fatal. Pneumonitis often resolves with steroids, but some cases are steroid refractory, leading to a relapsing and remitting course in milder cases or the need for salvage therapies in more severe cases. Here, we present two patients with NSCLC who developed severe pneumonitis following therapy with nivolumab and pembrolizumab. While one patient improved with steroids and infliximab, the other patient failed to respond to steroids and subsequently died. These cases demonstrate the highly variable presentation and therapeutic responses seen in patients with pneumonitis following anti-PD-1 therapy and illustrate that severe cases can often present refractory to steroid therapy.

  • immunological products and vaccines
  • immunology
  • lung cancer (oncology)
  • unwanted effects / adverse reactions
  • cancer intervention

Statistics from Altmetric.com

Footnotes

  • Contributors NA, LM, CH, PP and VP were involved in the care of patients, data acquisition and interpretation, and drafting of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.